Detalles de la búsqueda
1.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 23(9): 1167-1179, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35908558
2.
Signature of Spin-Resolved Quantum Point Contact in p-Type Trilayer WSe2 van der Waals Heterostructure.
Nano Lett
; 21(18): 7534-7541, 2021 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34472869
3.
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
; 149(2): 403-408, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33709428
4.
Complex Systems in Phase Space.
Entropy (Basel)
; 22(10)2020 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33286872
5.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31563517
6.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 420-435, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30718072
7.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Lancet Oncol
; 20(8): 1109-1123, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31301962
8.
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Oncologist
; 23(12): 1407-e136, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29853658
9.
Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Gastric Cancer
; 21(2): 276-284, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634748
10.
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Int J Cancer
; 140(2): 431-439, 2017 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27681944
11.
On the Interpretation of the Hazard Ratio and Communication of Survival Benefit.
Oncologist
; 22(4): 484-486, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28314839
12.
Ferroelectric-Domain-Patterning-Controlled Schottky Junction State in Monolayer MoS_{2}.
Phys Rev Lett
; 118(23): 236801, 2017 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28644638
13.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Br J Cancer
; 115(8): 974-982, 2016 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27623234
14.
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Oncologist
; 21(4): 402-3, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26984445
15.
Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.
Gastroenterology
; 148(2): 367-78, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25447851
16.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 383(9911): 31-39, 2014 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24094768
17.
Guidance on the management of diarrhoea during cancer chemotherapy.
Lancet Oncol
; 15(10): e447-60, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25186048
18.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1224-35, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25240821
19.
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Lancet Oncol
; 15(8): 894-904, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24950987
20.
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Lancet Oncol
; 14(6): 481-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23594787